Symptoms and signs

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

Thursday, March 4, 2021 - 8:30am

Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.

Key Points: 
  • Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.
  • "PsyCollage ensures we are moving in the right direction in our mission to provide alternative and effective treatment options for psychological and physiological pain," said Kelsey Ramsden, President & CEO, MINDCURE.
  • "Ibogaine has centuries of therapeutic history reinforcing its potential to heal pain.
  • MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health.

Global Healthtech Innovator NuroKor Accelerates US Expansion With Major New 5 Year Medi-Launch Partners Partnership and International Investment

Wednesday, March 3, 2021 - 12:43pm

Leading bioelectronic innovator NuroKor BioElectronics has announced plans to ramp up its US expansion, following 12 months of rapid growth during which the companys half-year sales rose by 156%.

Key Points: 
  • Leading bioelectronic innovator NuroKor BioElectronics has announced plans to ramp up its US expansion, following 12 months of rapid growth during which the companys half-year sales rose by 156%.
  • Our partnership with Medi-Launch Partners will be instrumental in ensuring we are able to distribute as far and wide as possible, reaching those who need highly effective, non-invasive pain relief.
  • As the only life sciences company of its kind worldwide, NuroKor is playing an important role in changing the way medical professionals and patients approach pain management.
  • The latest clinical investor to join the NuroKor team is Dr Alaina Edgemon, head of the Florida Natural Medicine & Pain Centre.

CCHP Partners with Kiio to Support Medicaid and Marketplace Members During COVID-19 with an Evidence-Based Pain Management Solution

Tuesday, March 2, 2021 - 5:35pm

CCHP initially rolled Kiio out to its Medicaid and Marketplace members in early 2019 and saw very strong results for Kiio participants in the first year.

Key Points: 
  • CCHP initially rolled Kiio out to its Medicaid and Marketplace members in early 2019 and saw very strong results for Kiio participants in the first year.
  • Members using Kiio experienced a 61% reduction in pain and a 52% improvement in function on average.
  • Also, 90% of members said Kiio helped them learn to better manage their pain.
  • We are proud to serve over 160,000 members between our two products, Medicaid and Together with CCHP Marketplace product.

Assertio Holdings, Inc. to Present at Virtual Roth Conference on Monday, March 15, 2021

Monday, March 1, 2021 - 9:01pm

A replay of the webcast will also be available following the live presentation on the investor section of the Company's website.

Key Points: 
  • A replay of the webcast will also be available following the live presentation on the investor section of the Company's website.
  • The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation.
  • These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio.
  • Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.

National Spine and Pain Centers Names Douglas Badertscher President

Tuesday, February 23, 2021 - 6:12pm

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.

Key Points: 
  • ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.
  • Most recently, Badertscher served as President and COO of Pain Specialists of America.
  • About National Spine and Pain Centers:
    For more than 30 years, NSPC affiliated physicians have been pioneers in the relief of chronic and acute pain through minimally invasive procedures and leading-edge clinical research.
  • Medical services provided by independently operated physician practices branded as National Spine and Pain Centers and other affiliated brands.

Zoetis Receives European Commission Marketing Authorization for Solensia® (frunevetmab), a New Therapy for Feline Osteoarthritis Pain

Monday, February 22, 2021 - 8:00am

Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain.
  • OA pain in cats remains vastly undertreated, and Solensia is a prime example of our commitment to meaningful innovation in feline medicines.
  • By alleviating pain, Solensia helps generally improve physical activity level, sociability and quality of life of cats with OA.
  • A total of 76% of cat owners reported sustained improvement in signs of pain when their cats were treated with Solensia.

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results After the Close of Markets on Thursday, March 11, 2021

Thursday, February 18, 2021 - 9:01pm

The replay will be available approximately two hours after the call on Assertios investor website.

Key Points: 
  • The replay will be available approximately two hours after the call on Assertios investor website.
  • The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation.
  • These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio.
  • Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.

2021 Pipeline Insights on the Postoperative Pain Industry - ResearchAndMarkets.com

Wednesday, February 17, 2021 - 2:08pm

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape.
  • "Postoperative pain - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Postoperative pain pipeline landscape is provided which includes the disease overview and Postoperative pain treatment guidelines.
  • Postoperative pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Therabody Raises Strategic Investment To Advance Innovation And Accelerate Global Growth

Wednesday, February 17, 2021 - 2:00pm

Therabody products are used by medical professionals and consumers for treatment of pain, injuries, and ailments including chronic neck and back pain.

Key Points: 
  • Therabody products are used by medical professionals and consumers for treatment of pain, injuries, and ailments including chronic neck and back pain.
  • "Ben, Dr. Jason, and the entire Therabody team are passionate about helping people and delivering innovative products and experiences.
  • We see a massive opportunity for the brand on a global level, and we're looking forward to their continued growth ahead."
  • "We are excited to back Therabody as it leads the way in innovation at the intersection of fitness, wellness, and technology," said Nate Raabe, managing partner of Rx3 Growth Partners.

Non-Invasive Vagus Nerve Stimulation May Treat Migraine in Patients with COVID-19, According to Neurologist Stephen D. Silberstein, M.D.

Tuesday, February 16, 2021 - 2:00pm

Although formal statistics on the clinical features of COVID-19 headaches do not exist at this stage of the pandemic, people are reporting migraine-like headaches.

Key Points: 
  • Although formal statistics on the clinical features of COVID-19 headaches do not exist at this stage of the pandemic, people are reporting migraine-like headaches.
  • They describe a throbbing and/or pressure like pain that is aggravated by routine movements such as bending over.
  • Many patients with COVID-19 are seeking treatment for their headaches, says Stephen D Silberstein, MD, Director of Thomas Jefferson Universitys Jefferson Headache Center .
  • Patients can be reluctant to start a prescription drug if over the counter medication such as ibuprofen doesnt help.